{"id":"cladribine-high-dose","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression/neutropenia"},{"rate":null,"effect":"Lymphopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cladribine is a deoxyadenosine analog that is phosphorylated intracellularly and incorporated into DNA, causing double-strand breaks and apoptosis primarily in lymphocytes. It has preferential activity against T cells and B cells due to their high deoxycytidine kinase activity and low 5'-nucleotidase activity. The high-dose formulation is designed to achieve rapid lymphocyte depletion for immunosuppressive or anti-cancer effects.","oneSentence":"Cladribine is a purine nucleoside analog that depletes lymphocytes by being incorporated into DNA and causing strand breaks, leading to selective destruction of immune cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:06:15.071Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hairy cell leukemia"},{"name":"Chronic lymphocytic leukemia"},{"name":"Multiple sclerosis (relapsing-remitting)"}]},"trialDetails":[{"nctId":"NCT06463587","phase":"PHASE3","title":"Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)","status":"RECRUITING","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2024-06-25","conditions":"Generalized Myasthenia Gravis","enrollment":264},{"nctId":"NCT06713837","phase":"PHASE3","title":"IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.","status":"RECRUITING","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2025-02-27","conditions":"Acute Myeloid Leukemia, Relapse/Recurrence","enrollment":339},{"nctId":"NCT01515527","phase":"PHASE2","title":"Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-02-07","conditions":"Leukemia","enrollment":160},{"nctId":"NCT03926624","phase":"PHASE3","title":"Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage","status":"TERMINATED","sponsor":"Delta-Fly Pharma, Inc.","startDate":"2019-11-22","conditions":"Leukemia, Myeloid, Acute","enrollment":167},{"nctId":"NCT04047628","phase":"PHASE3","title":"Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-19","conditions":"Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis","enrollment":156},{"nctId":"NCT05365035","phase":"PHASE2","title":"A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-09-23","conditions":"Myelodysplastic Syndromes, Myeloproliferative Chronic Myelomonocytic Leukemia","enrollment":60},{"nctId":"NCT06232655","phase":"PHASE2","title":"Cladribine Venetoclax in Monocytic AML","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2024-02-08","conditions":"Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT06474663","phase":"PHASE1","title":"A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-07-31","conditions":"Refractory Acute Leukemia, Relapsed Acute Leukemia","enrollment":""},{"nctId":"NCT04195945","phase":"PHASE2","title":"CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-03-11","conditions":"Acute Myeloid Leukemia, Myeloid Neoplasm","enrollment":60},{"nctId":"NCT05766514","phase":"PHASE2","title":"Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction","status":"WITHDRAWN","sponsor":"University of Florida","startDate":"2025-04","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":""},{"nctId":"NCT03150004","phase":"PHASE2","title":"Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients with Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)","status":"TERMINATED","sponsor":"Medical College of Wisconsin","startDate":"2017-06-14","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":53},{"nctId":"NCT04776213","phase":"PHASE4","title":"Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension)","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2021-02-23","conditions":"Multiple Sclerosis","enrollment":280},{"nctId":"NCT04196010","phase":"PHASE1","title":"Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms","status":"TERMINATED","sponsor":"University of Washington","startDate":"2020-05-08","conditions":"Myeloid Neoplasm, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":13},{"nctId":"NCT03531918","phase":"PHASE1, PHASE2","title":"Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2018-09-14","conditions":"Acute Myeloid Leukemia","enrollment":66},{"nctId":"NCT05578378","phase":"PHASE2, PHASE3","title":"Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALL","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-01-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":32},{"nctId":"NCT03012672","phase":"PHASE2","title":"Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm","status":"COMPLETED","sponsor":"University of Washington","startDate":"2016-12-30","conditions":"Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Myeloid Neoplasm","enrollment":50},{"nctId":"NCT00725985","phase":"PHASE3","title":"Oral Cladribine in Early Multiple Sclerosis (MS)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2008-12-31","conditions":"Multiple Sclerosis","enrollment":617},{"nctId":"NCT00641537","phase":"PHASE3","title":"CLARITY Extension Study","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2008-02-29","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":867},{"nctId":"NCT02272478","phase":"PHASE2, PHASE3","title":"Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations","status":"UNKNOWN","sponsor":"Cardiff University","startDate":"2014-10-30","conditions":"Acute Myeloid Leukaemia, Myelodysplastic Syndrome","enrollment":1600},{"nctId":"NCT02044796","phase":"PHASE1, PHASE2","title":"Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2014-01-23","conditions":"Acute Biphenotypic Leukemia, de Novo Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome","enrollment":199},{"nctId":"NCT02676856","phase":"NA","title":"Hematopoietic Stem Cell Microtransplantation for in AML","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2016-02","conditions":"Acute Myeloid Leukemia","enrollment":40},{"nctId":"NCT00708721","phase":"PHASE1, PHASE2","title":"Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia","status":"TERMINATED","sponsor":"University of Utah","startDate":"2008-03","conditions":"Cancer, Chronic Myelomonocytic Leukemia","enrollment":11},{"nctId":"NCT00136084","phase":"PHASE3","title":"Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2002-08","conditions":"Leukemia, Myelocytic, Acute","enrollment":238},{"nctId":"NCT00002833","phase":"PHASE2","title":"Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"1994-10","conditions":"Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes","enrollment":53},{"nctId":"NCT00126321","phase":"PHASE2","title":"Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML)","status":"UNKNOWN","sponsor":"University Hospital, Bonn","startDate":"2004-11","conditions":"Leukemia, Myelocytic, Acute","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":85,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Cladribine High Dose","genericName":"Cladribine High Dose","companyName":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","companyId":"merck-healthcare-kgaa-darmstadt-germany-an-affiliate-of-merck-kgaa-darmstadt-ger","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cladribine is a purine nucleoside analog that depletes lymphocytes by being incorporated into DNA and causing strand breaks, leading to selective destruction of immune cells. Used for Hairy cell leukemia, Chronic lymphocytic leukemia, Multiple sclerosis (relapsing-remitting).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}